|
Canada-0-Engineering Azienda Directories
|
Azienda News:
- ESR1-mutated, ER+ HER2- mBC Treatment | ORSERDU® (elacestrant)
Learn about ORSERDU®, the only NCCN Clinical Practice Guidelines in Oncology–recommended treatment option for ESR1-mutated, HR+ HER2- mBC
- Real-World Outcomes of Elacestrant in ER+, HER2−, ESR1-Mutant . . .
The EMERALD trial led to the approval of elacestrant for estrogen receptor (ER)–positive, HER2-negative, estrogen receptor 1 (ESR1)–mutated advanced or metastatic breast cancer (mBC) with disease progression following at least one line of endocrine
- Elacestrant combinations in patients (pts) with ER+ HER2- locally . . .
Elacestrant has the potential to become an ET backbone for multiple targeted agents, providing an all-oral treatment option in pts with ER+ HER2- mBC, delaying chemo or ADC-based regimens Clinical trial information: NCT05563220
- ESR1-Mutated ER+ HER2- mBC Therapy - ORSERDU® (elacestrant)
Evaluate ORSERDU®, a treatment option for ESR1-mutated, ER+ HER2- advanced or metastatic breast cancer following disease progression on endocrine therapy
- Elacestrant in ESR1-mutant, endocrine-responsive metastatic breast . . .
For patients with hormone receptor-positive human epidermal growth factor receptor 2 (HER2)-negative (HR+ HER2−) metastatic breast cancer (mBC) progressed on first-line endocrine therapy plus a cyclin-dependent kinase 4 and 6 inhibitor (CDK4 6i), fulvestrant, a selective estrogen receptor degrader (SERD) administered intramuscularly, represented the only monotherapy option until the approval
- ELEVATE Trial Shows Promise of Elacestrant Combinations in ER+ HER2– mBC
Early results from the ELEVATE trial (NCT05563220), a phase 1b 2 study of elacestrant (Orserdu) given in combination with various targeted therapies, showed promise when used for the treatment of patients with estrogen receptor-positive (ER+) HER2-negative (HER2–) metastatic breast cancer (mBC) who have received prior endocrine therapy and CDK4 6 inhibitors 1 While endocrine therapy plus
- Positive Safety Data Enforces Elacestrant as Treatment Option in HER2 . . .
In January 2023, the FDA approved elacestrant for the treatment of postmenopausal women or adult men with ER-positive, HER2-negative, ESR1 -mutated advanced or metastatic breast cancer with disease progression following at least 1 line of ET 2
- Elacestrant: A Novel Therapy for ER+ HER2- Metastatic Breast Cancer
The approval of elacestrant as a subsequent line of therapy for patients with ER+ HER2- metastatic breast cancer offers a novel therapeutic option in a setting that previously had limited options
- Elacestrant in ER+, HER2- Metastatic Breast Cancer with ESR1 . . . - PubMed
The duration of prior ET+CDK4 6i ≥12 months in metastatic breast cancer was associated with a clinically meaningful improvement in PFS for elacestrant compared with SOC and was consistent across all subgroups evaluated in patients with ER+, HER2-, ESR1-mutated tumors
- FDA approves elacestrant for ER-positive, HER2-negative, ESR1-mutated . . .
Drug Approvals and Databases Resources for Information | Approved Drugs FDA approves elacestrant for ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer
|
|